
There is still hope that obesity treatment Wegovy will be authorized for the European market before the end of the year.
At least, that is what Novo Nordisk's CEO Lars Fruergaard Jørgensen said in an interview with Bloomberg News, as reported by the media relations team at the Danish pharmaceutical firm.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app